These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Extended adjuvant therapy for breast cancer--how much is enough? Prowell TM; Stearns V J Natl Cancer Inst; 2007 Dec; 99(24):1825-7. PubMed ID: 18073372 [No Abstract] [Full Text] [Related]
3. Long-term outcomes of aromatase inhibition for breast cancer. Toi M Lancet Oncol; 2008 Jan; 9(1):8-10. PubMed ID: 18177815 [No Abstract] [Full Text] [Related]
4. Anastrozole for breast cancer: recent advances and ongoing challenges. Buzdar AU Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927 [TBL] [Abstract][Full Text] [Related]
5. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS; Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680 [TBL] [Abstract][Full Text] [Related]
6. Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer. Buzdar AU J Clin Oncol; 2007 May; 25(15):2147-8; author reply 2148. PubMed ID: 17513830 [No Abstract] [Full Text] [Related]
7. Adjuvant aromatase inhibitors for breast cancer. Howell A Lancet; 2005 Aug 6-12; 366(9484):431-3. PubMed ID: 16084234 [No Abstract] [Full Text] [Related]
8. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)]. Bruntsch U MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697 [No Abstract] [Full Text] [Related]
9. Is long-term adjuvant treatment of breast cancer with anastrozole indicated? Doggrell SA Expert Opin Pharmacother; 2008 Jun; 9(9):1619-22. PubMed ID: 18518790 [TBL] [Abstract][Full Text] [Related]
13. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061 [TBL] [Abstract][Full Text] [Related]
15. Obesity and endocrine therapy: host factors and breast cancer outcome. Goodwin PJ Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791 [TBL] [Abstract][Full Text] [Related]
16. [Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)]. Thürlimann B; Senn HJ Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):143-6. PubMed ID: 15990439 [TBL] [Abstract][Full Text] [Related]
17. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer. Monnier AM Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927 [TBL] [Abstract][Full Text] [Related]
18. [The ATAC study on adjuvants in breast cancer]. Bravi S Suppl Tumori; 2004; 3(4):S15. PubMed ID: 15206200 [No Abstract] [Full Text] [Related]
19. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen. Carpenter R Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017 [TBL] [Abstract][Full Text] [Related]
20. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women. Nabholtz JM Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]